An Integrated Circulating Biomarker Index for Overall Survival in Metastatic Breast Cancer Treated with Chemotherapy: A Retrospective Cohort Study.
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Circulating biomarkers associated with tumor–immune interactions and clinical outcomes in breast cancer are generally evaluated individually. We investigated their prognostic significance in patients with metastatic breast cancer (MBC) receiving chemotherapy and developed an integrated biomarker index for overall survival (OS). Methods We retrospectively analyzed 43 patients with MBC who were receiving chemotherapy. Baseline circulating levels of tumor necrosis factor-α (TNF-α), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), IL-8, transforming growth factor-β (TGF-β), and thymidine kinase 1 (TK1) were measured. Biomarkers associated with OS were combined to construct the OS Integrated Biomarker Index (OS-IBI). Associations of the OS-IBI with survival and peripheral immune and inflammatory parameters were evaluated. Results In univariable Cox proportional hazards analysis, TNF-α ( p = 0.008), sIL-2R ( p < 0.001), IL-6 ( p = 0.001), and TK1 ( p = 0.003) were significantly associated with shorter OS and were subsequently incorporated into the OS-IBI. The OS-IBI showed numerically greater discrimination for OS than any individual biomarker (AUC 0.801, 95% CI: 0.658–0.944) and remained independently associated with shorter OS in multivariable analysis (HR 1.82, 95% CI: 1.31–2.53; p < 0.001). Bootstrap internal validation yielded an optimism-corrected C-index of 0.817. Higher OS-IBI values were associated with lower proportions of CD4 + lymphocytes and higher proportions of myeloid-derived suppressor cells, as well as unfavorable systemic inflammatory parameters. Conclusions The OS-IBI, integrating circulating biomarkers related to inflammation, immune activation, and tumor proliferation, was independently associated with OS and with peripheral features of systemic immune dysregulation. These findings warrant validation in larger, independent cohorts.
Source: Research Square
Institutions: Hyogo Medical University, Niigata University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: metastatic breast cancer, circulating biomarkers, overall survival, prognostic factors, chemotherapy, TNF-α, soluble interleukin-2 receptor, interleukin-6, interleukin-8, TGF-beta, thymidine kinase 1, systemic inflammation, tumor-immune interactions, myeloid-derived suppressor cells, CD4+ T cells, immune dysregulation
Open Access status: green
OpenAlex ID: W7236569070
